NASDAQ:FHTX Foghorn Therapeutics (FHTX) Stock Price, News & Analysis $4.67 -0.16 (-3.31%) Closing price 09/9/2026 04:00 PM EasternExtended Trading$4.85 +0.18 (+3.85%) As of 04:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Foghorn Therapeutics Stock (NASDAQ:FHTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Foghorn Therapeutics alerts:Sign Up Key Stats Today's Range$4.66▼$4.9050-Day Range$4.53▼$7.0752-Week Range$3.27▼$7.61Volume198,603 shsAverage Volume370,434 shsMarket Capitalization$277.30 millionP/E RatioN/ADividend YieldN/APrice Target$11.43Consensus RatingModerate Buy Company Overview Foghorn Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel epigenetic therapies for cancer. The company leverages its proprietary Targeted Protein Discovery Platform to identify and design small-molecule inhibitors that modulate chromatin regulatory proteins involved in tumor growth and survival. By targeting the mechanisms that control gene expression, Foghorn seeks to address unmet needs in oncology through precision medicine. The company’s lead candidate, FHD-286, is a selective inhibitor of variant SWI/SNF chromatin remodeling complexes and is currently being evaluated in Phase 1 clinical trials for patients with solid tumors harboring specific SMARCA2 and SMARCA4 alterations. In addition to FHD-286, Foghorn maintains a pipeline of preclinical programs aimed at other chromatin targets, with the goal of advancing multiple development candidates into the clinic over the coming years. Founded in 2015 and headquartered in Cambridge, Massachusetts, Foghorn Therapeutics was established with support from leading life-science investors. The company operates research and development activities in the United States and collaborates with academic and industry partners to accelerate the translation of its discoveries into potential therapeutic options for patients worldwide. Under the leadership of President and Chief Executive Officer Robert Mulroy, PhD, Foghorn has built a multidisciplinary team with expertise in epigenetics, medicinal chemistry, structural biology and translational medicine. The company’s strategic vision emphasizes innovation in chromatin biology and a commitment to developing differentiated treatments for oncology.AI Generated. May Contain Errors. Read More Foghorn Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreFHTX MarketRank™: Foghorn Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 550th out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingFoghorn Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialFoghorn Therapeutics has a consensus price target of $11.43, representing about 144.7% upside from its current price of $4.67.Amount of Analyst CoverageFoghorn Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Foghorn Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Foghorn Therapeutics are expected to decrease in the coming year, from ($0.81) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Foghorn Therapeutics is -4.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Foghorn Therapeutics is -4.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Foghorn Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.31% of the float of Foghorn Therapeutics has been sold short.Short Interest Ratio / Days to CoverFoghorn Therapeutics has a short interest ratio ("days to cover") of 7.13.Change versus previous monthShort interest in Foghorn Therapeutics has recently increased by 11.42%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFoghorn Therapeutics does not currently pay a dividend.Dividend GrowthFoghorn Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News SentimentN/A News SentimentFoghorn Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Foghorn Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for FHTX on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Foghorn Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Foghorn Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders9.02% of the stock of Foghorn Therapeutics is held by insiders.Percentage Held by Institutions61.55% of the stock of Foghorn Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Foghorn Therapeutics' insider trading history. Receive FHTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Foghorn Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FHTX Stock News HeadlinesFoghorn Therapeutics Inc. (NASDAQ:FHTX) Given Average Recommendation of "Moderate Buy" by AnalystsSeptember 2, 2026 | americanbankingnews.comH.C. Wainwright Reaffirms Their Buy Rating on Foghorn Therapeutics (FHTX)August 21, 2026 | theglobeandmail.comBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 million shares worth about 716 million dollars, while Vanguard owns 48 million shares worth nearly 1.1 billion dollars. The company generates approximately 3.2 billion dollars in operating income against a market value of only about 8 billion dollars, and it has signed a multi-year AI agreement with Palantir to improve equipment reliability and well performance. | Monument Traders Alliance (Ad)Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate UpdateAugust 6, 2026 | globenewswire.comStep Pharma announces the appointment of Neil Gallagher as Non-Executive DirectorJuly 1, 2026 | globenewswire.comFoghorn Therapeutics Inc. (FHTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comFoghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026June 5, 2026 | globenewswire.comFoghorn Therapeutics Highlights Q1 Progress in Oncology PipelineMay 22, 2026 | theglobeandmail.comSee More Headlines FHTX Stock Analysis - Frequently Asked Questions How have FHTX shares performed this year? Foghorn Therapeutics' stock was trading at $5.40 at the beginning of 2026. Since then, FHTX stock has decreased by 13.5% and is now trading at $4.67. How were Foghorn Therapeutics' earnings last quarter? Foghorn Therapeutics Inc. (NASDAQ:FHTX) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.15. The company had revenue of $16.10 million for the quarter, compared to analysts' expectations of $6.81 million. When did Foghorn Therapeutics IPO? Foghorn Therapeutics (FHTX) raised $120 million in an initial public offering on Friday, October 23rd 2020. The company issued 7,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, Morgan Stanley and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Foghorn Therapeutics' major shareholders? Foghorn Therapeutics' top institutional investors include BlackRock Inc. (4.47%), Squarepoint Ops LLC (0.22%), SCS Capital Management LLC (0.18%) and Bank of New York Mellon Corp (0.14%). View institutional ownership trends. How do I buy shares of Foghorn Therapeutics? Shares of FHTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Foghorn Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Foghorn Therapeutics investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), NVIDIA (NVDA), Netflix (NFLX), Meta Platforms (META) and Alphabet (GOOG). Company Calendar Last Earnings8/06/2026Today9/09/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 10 days, FHTX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:FHTX CIK1822462 Webfoghorntx.com Phone617-586-3100FaxN/AEmployees120Year Founded2016Price Target and Rating Average Price Target for Foghorn Therapeutics$11.43 High Price Target$13.00 Low Price Target$10.00 Potential Upside/Downside+144.7%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.28 million Net Margins-175.78% Pretax Margin-175.78% Return on EquityN/A Return on Assets-31.17% Debt Debt-to-Equity RatioN/A Current Ratio3.36 Quick Ratio3.36 Sales & Book Value Annual Sales$30.91 million Price / Sales8.97 Cash FlowN/A Price / Cash FlowN/A Book Value($1.92) per share Price / Book-2.43Miscellaneous Outstanding Shares59,380,000Free Float54,028,000Market Cap$277.30 million OptionableOptionable Beta2.86 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:FHTX) was last updated on 9/10/2026 by MarketBeat.com Staff. From Our PartnersWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...Monument Traders Alliance | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...Banyan Hill Publishing | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FHTX Stock Alerts